Hiroaki Nomoto ¹, Yoshikazu Hayashi, Satoshi Shinozaki, Tomonori Yano, Keijiro Sunada, Wataru Sasao, Aya Kitamura, Mai Ohashi, Shuhei Hiyama, Alan Kawarai Lefor, Hironori Yamamoto, Clin J Gastroenterol 2014 Dec;7(6):476-80.

UC-associated pulmonary lesions can be treated without steroid administration, and we suggest that this strategy is an option for a patient with UC-associated pulmonary lesions that cannot be differentiated from an infection.

https://pubmed.ncbi.nlm.nih.gov/25491905/

K Sugiura ¹, K Haruna, Y Suga, M Akiyama, J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1835-6.

https://pubmed.ncbi.nlm.nih.gov/24490830/

Valeria D’Ovidio ¹, Donatella Meo, Maria Gozer, Marco E Bazuro, Piero Vernia, J Clin Apher. 2015 Feb;30(1):55-7.

To minimize symptoms and the risk of severe clinical relapse, a maintenance GMA treatment was performed throughout pregnancy. The course of pregnancy was uneventful with no side effects; the mother and the baby were all healthy and well at the delivery.

https://pubmed.ncbi.nlm.nih.gov/25181523/

Hiroki Takahashi ¹, Kaori Sugawara, Mikako Sugimura, Masahiro Iwabuchi, Yutaka Mano, Katsuaki Ukai, Keiichi Tadokoro, Arch Gynecol Obstet. 2013 Aug;288(2):341-7.

In these three cases with active ulcerative colitis during pregnancy, granulocytapheresis as a non-pharmacologic treatment was effective and safe. In case 3 that did not respond well to the initial granulocytapheresis sessions, a moderate dose of prednisolone enhanced the efficacy of granulocytapheresis and tapering of prednisolone shortly after administration was not associated with relapse.

https://pubmed.ncbi.nlm.nih.gov/23404436/

Yuko Higashi ¹, Mitsuyoshi Shimokawa, Kazuhiro Kawai, Takuro Kanekura, J Dermatol. 2013 Dec;40(12):1042-4.

We present a 39-year-old pregnant woman with Behçet’s disease who was treated successfully with granulocyte and monocyte adsorption apheresis (GMA). There were no complications or adverse effects during her pregnancy and delivery. The neonate manifested no abnormalities.

https://pubmed.ncbi.nlm.nih.gov/24303809/

Takumi Fukuchi ¹, Hiroshi Nakase, Minoru Matsuura, Takuya Yoshino, Takahiko Toyonaga, Katsuyuki Ohmori, Satoshi Ubukata, Aya Ueda, Takaaki Eguchi, Hiroshi Yamashita, Dai Ito, Kiyoshi Ashida, J Crohns Colitis. 2013 Nov;7(10):803-11.

Intestinal inflammation might trigger CMV reactivation in a subpopulation of active UC patients without CS treatment. GMAA could be a promising option for active UC positive for CMV.

https://pubmed.ncbi.nlm.nih.gov/23352104/

https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/179280

Tsutomu Mizoshita ¹, Satoshi Tanida ², Shigeru Kusumoto ³, Keiji Ozeki ², Hironobu Tsukamoto ², Masahide Ebi ², Yoshinori Mori ², Hiromi Kataoka ², Takeshi Kamiya ², Takashi Joh ²,Clin J Gastroenterol. 2012 Aug;5(4):302-6.

A 52-year-old woman was diagnosed with Crohn’s disease (CD) of the large intestine in May 2001. Her disease was accompanied by the development of chronic myelogenous leukemia (CML) in December 2003. Remission of her CML has been maintained up to the present with tyrosine kinase inhibitors. Clinical and endoscopic remission of the patient’s CD was maintained with salazosulfapyridine (3000 mg/day) and occasional prednisolone (≤20 mg/day) from 2001 to 2010. However, in December 2010 the patient complained of abdominal pain and diarrhea more than 10 times a day. Endoscopy showed serpiginous (snake-like) ulcers in the transverse colon and aphthous ulcers in the sigmoid colon. Intensive granulocyte and monocyte adsorptive apheresis (GMA) (two sessions per week, total of ten sessions) was performed, and the CD activity index (CDAI) decreased from 259 to 175. Six adalimumab injections were administered to improve the remaining inflammatory mucosa. Two months after induction therapy with adalimumab, the CDAI decreased from 175 to 107 without side effects. Endoscopy revealed mucosal healing of the colonic inflammatory lesions. We experienced a case of a patient with CD accompanied by CML. We successfully treated the patient by a combination of intensive GMA and adalimumab

https://pubmed.ncbi.nlm.nih.gov/26182398/

Takuya Yoshino ¹, Hiroshi Nakase, Minoru Matsuura, Kayoko Matsumura, Yusuke Honzawa, Takumi Fukuchi, Kenji Watanabe, Mitsuyuki Murano, Tomoyuki Tsujikawa, Ken Fukunaga, Takayuki Matsumoto, Tsutomu Chiba, Digestion. 2011;84(1):3-9.

The colectomy ratio tends to be high in refractory UC patients with recurrent CMV reactivation or infection. Therefore, GMA might be a safe and effective treatment for UC patients positive for CMV because it does not induce CMV reactivation.

https://pubmed.ncbi.nlm.nih.gov/21311190/

https://repository.kulib.kyoto-u.ac.jp/dspace/handle/2433/183987

H. Nakase, M. Matsuura, T. Chibam , https://doi.org/10.1111/j.1365-2036.2010.04552.x

These new data suggest that GMAA might be safe and effective for UC patients positive for CMV because it does not cause CMV reactivation. Because CMV reactivation might affect the clinical outcome of patients with refractory UC,⁵ GMAA could be a promising option for UC patients with CMV infection. A new clinical trial with a larger number of patients is ongoing to evaluate further the effects of GMA on UC patients with CMV infection.

https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2010.04552.x

Kosaku Moribata ¹, Jun Kato, Sae Iimura, Satoshi Yoshida, Naoki Shingaki, Kazuki Ueda, Hisanobu Deguchi, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Hideyuki Tamai, Masao Ichinose, J Clin Apher. 2011;26(4):225-7.

We report a case of a 16-year-old male who suffered from Crohn’s disease (CD) with esophageal involvement, showing remarkable improvement with granulocyte/monocyte adsorption (GMA). The patient had been diagnosed as ileocolic CD and was treated with 5-aminosalicylate. He was admitted to our hospital with symptoms of fever, diarrhea, and odynophagia. Endoscopic examinations revealed that the exacerbation of ileocolic ulcers, and advent of ulcers in esophagus. Because of the patient’s refusal to receive corticosteroids, immunomodulators, or biologics, he underwent GMA twice a week. After 10 sessions of GMA, he entered remission with significant decrease in clinical activity. In addition, endoscopic examinations showed remarkable improvement of ileocolic ulcers and disappearance of esophageal lesions. No adverse events were observed. GMA could be effective for manifestations of CD in gastrointestinal tract other than ileum or colon.

https://pubmed.ncbi.nlm.nih.gov/21786316/